Skip to content
Catalyst brief · Phase 3 readout · 26 days

Donidalorsen: Donidalorsen in Hereditary Angioedema

Ionis Pharmaceuticals, Inc. · $IONS · built 19 Nov 2026 from 19 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's main goal is to measure the percentage of participants with at least one treatment-emergent adverse event, which may not be the most convincing outcome for efficacy, and the open-label design without blinding may introduce bias. F3 F4
  • The trial plans to enrol 154 patients, which is an increase from the initial target of 114, and has only one study arm, which may limit the strength of the results. F2 F6

Base rates

  • Historically, 57.8% of Phase 3 programmes in rare disease moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F11
  • The company's record shows that 54% of its active Phase 2 and 3 trials have had their dates moved back by more than 6 months. F12
  • The DataCutoff timing model estimates this trial will finish close to its registry date. F10
  • On average, IONS's past trial-result days have had an absolute share move of 6.6%, but this is just an average and not a forecast for this trial. F13

Filings

  • The company has a cash position of $1.9B and a runway of about 42 months, which is beyond the primary completion date of the Donidalorsen trial. F14 F15
  • Insiders have made some open-market transactions in the last 90 days, including 1 purchase and 2 sales, with the largest purchase being $148K. F16 F17
  • The primary completion date of the Donidalorsen trial is estimated to be Dec 2026, which is 26 days from 19 Nov 2026. F8

The case for

  • The company's cash position and runway of about 42 months provide a stable financial foundation for the trial to complete as planned, reducing the risk of delays due to funding issues. F14 F15

The case against

  • The trial's design may introduce bias and its main goal may not be convincing for efficacy, which could lead to a failed trial or delayed results. F3 F4
  • The company has a history of delaying trials, with 54% of its active Phase 2 and 3 trials having their dates moved back by more than 6 months, which could happen to this trial as well. F12

Open questions

  • Will the trial meet its primary completion date of Dec 2026?
  • Can Donidalorsen demonstrate a favourable safety profile despite the open-label design?

6 AI sentences were removed by the fact check.

The facts

The trial

  • F1Donidalorsen is a Phase 3 trial of Donidalorsen in Hereditary Angioedema, sponsored by Ionis Pharmaceuticals, Inc. (IONS). source ↗
  • F2The trial plans to enrol 154 patients; the target first registered was 114. source ↗

What counts as success

  • F3Main goal as written in the registry: Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity. source ↗
  • F4Blinding: open label (no blinding). source ↗
  • F5The main goal is measured over: Up to approximately 70 weeks, plus 104 weeks for Group 1; up to approximately 76 weeks, plus 104 weeks for Group 2. source ↗
  • F6Number of study arms: 1. source ↗

When

  • F8The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F9That date is 26.0 months later than the date first registered for this trial (Oct 2024). source ↗
  • F10The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗

Recruitment

Base rates

  • F11Historically 57.8% of Phase 3 programmes in rare disease (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F1254% of IONS's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗
  • F13IONS has had 8 past trial-result days on record, with an average absolute share move of 6.6%. source ↗

Money, insiders and FDA

  • F14IONS reported $1.9B in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F15At the last 12 months' rate of spending (about $45M a month) that cash lasts about 42 months, to around Mar 2030, which is after the registry's primary completion date. source ↗
  • F16Insiders made 1 open-market purchases in the last 90 days, totalling $148K; the largest was $148K by the Director on 10 Nov 2026. source ↗
  • F17Insiders made 2 unplanned open-market sales in the last 90 days, totalling $61K. source ↗

Rivals

  • F18ADRX is running a Phase 3 trial of ADX-324 in the same condition, with a registry date of 30 Nov 2027. source ↗
  • F19BCRX is running a Phase 3 trial of berotralstat in the same condition, with a registry date of Aug 2031. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.